Interleukin 3- receptor targeted exosomes inhibit in vitro and in vivo Chronic Myelogenous Leukemia cell growth
暂无分享,去创建一个
Stefania Raimondo | Stefano Forte | Patrizia Diana | Girolamo Cirrincione | Simona Fontana | Francesca Monteleone | Gianluca Giavaresi | Giovanna Calabrese | L. Memeo | S. Raimondo | S. Forte | P. Diana | R. Alessandro | S. Fontana | G. Giavaresi | Lorenzo Memeo | Mauro Manno | Riccardo Alessandro | G. Calabrese | G. De Leo | Giacomo De Leo | D. Bellavia | M. Manno | S. Raccosta | F. Monteleone | Daniele Bellavia | Marta Cristaldi | Agostina Patinella | Samuele Raccosta | G. Cirrincione | M. Cristaldi | Agostina Patinella | Riccardo Alessandro | Stefania Raimondo | Giovanna Calabrese | Stefano Forte | Agostina Patinella | Lorenzo Memeo | Mauro Manno | Gianluca Giavaresi | Simona Fontana
[1] U. Testa,et al. CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies , 2014, Biomarker Research.
[2] E. Nievergall,et al. Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells. , 2014, Blood.
[3] M. Wood,et al. Exosomes for targeted siRNA delivery across biological barriers. , 2013, Advanced drug delivery reviews.
[4] A. Elmaagacli,et al. Additive antileukemia effects by GFI1B- and BCR–ABL-specific siRNA in advanced phase chronic myeloid leukemic cells , 2013, Cancer Gene Therapy.
[5] M. Konopleva,et al. SL‐401 and SL‐501, targeted therapeutics directed at the interleukin‐3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia , 2014, British journal of haematology.
[6] Wei Cao,et al. 胞外囊泡在恶性血液病中的研究进展 , 2013, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi.
[7] Dongmei Sun,et al. A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.
[8] J. Melo,et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. , 2000, Blood.
[9] K. Drescher,et al. Exosomal miRNAs: Biological Properties and Therapeutic Potential , 2012, Front. Gene..
[10] S. Raimondo,et al. Chronic myeloid leukemia-derived exosomes promote tumor growth through an autocrine mechanism , 2015, Cell Communication and Signaling.
[11] C. Verfaillie,et al. Gene therapy for chronic myelogenous leukemia (CML): a retroviral vector that renders hematopoietic progenitors methotrexate-resistant and CML progenitors functionally normal and nontumorigenic in vivo. , 1997, Blood.
[12] H. Kantarjian,et al. Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm. , 2015, Clinical lymphoma, myeloma & leukemia.
[13] J. Pinilla-Ibarz,et al. Long-term BCR-ABL1 Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia. , 2015, Anticancer research.
[14] J. Cooper,et al. Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice , 2014, Movement disorders : official journal of the Movement Disorder Society.
[15] Heikki Saari,et al. Microvesicle- and exosome-mediated drug delivery enhances the cytotoxicity of Paclitaxel in autologous prostate cancer cells. , 2015, Journal of controlled release : official journal of the Controlled Release Society.
[16] Meg Duroux,et al. A comprehensive overview of exosomes as drug delivery vehicles - endogenous nanocarriers for targeted cancer therapy. , 2014, Biochimica et biophysica acta.
[17] A. Elmaagacli,et al. Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia , 2007, Clinical and Experimental Medicine.
[18] Myung Soo Kim,et al. Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells. , 2016, Nanomedicine : nanotechnology, biology, and medicine.
[19] E. Coccia,et al. Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. , 2002, Blood.
[20] T. Mughal,et al. Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase , 2010, Biologics : targets & therapy.
[21] D. Richardson,et al. Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come , 2016, Pharmacological Reviews.
[22] Richa Gupta,et al. Exosomes as drug delivery vehicles for Parkinson's disease therapy. , 2015, Journal of controlled release : official journal of the Controlled Release Society.
[23] M. Manoharan,et al. RNAi therapeutics: a potential new class of pharmaceutical drugs , 2006, Nature chemical biology.
[24] M. Wood,et al. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes , 2011, Nature Biotechnology.
[25] S. Raimondo,et al. Exosomes as Intercellular Signaling Organelles Involved in Health and Disease: Basic Science and Clinical Applications , 2013, International journal of molecular sciences.
[26] I. Sargent,et al. Exosome-mediated delivery of siRNA in vitro and in vivo , 2012, Nature Protocols.
[27] Shinobu Ueda,et al. Systemically Injected Exosomes Targeted to EGFR Deliver Antitumor MicroRNA to Breast Cancer Cells. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.
[28] Jian Song,et al. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. , 2014, Biomaterials.
[29] Sérgio Simões,et al. Co‐encapsulation of anti‐BCR‐ABL siRNA and imatinib mesylate in transferrin receptor‐targeted sterically stabilized liposomes for chronic myeloid leukemia treatment , 2010, Biotechnology and bioengineering.
[30] P. Kuo,et al. PLK-1 Silencing in Bladder Cancer by siRNA Delivered With Exosomes. , 2016, Urology.
[31] Graça Raposo,et al. Exosomes--vesicular carriers for intercellular communication. , 2009, Current opinion in cell biology.
[32] R. Saha,et al. UV-spectrophotometric determination of imatinib mesylate and its application in solubility studies. , 2008, Die Pharmazie.
[33] H. Uludaǧ,et al. Progress in RNAi-mediated Molecular Therapy of Acute and Chronic Myeloid Leukemia. , 2015, Molecular therapy. Nucleic acids.
[34] H. Kantarjian,et al. Chronic myelogenous leukemia: update on biology and treatment. , 1999, Oncology.
[35] A. Engert,et al. Dendritic Cells Release HLA-B-Associated Transcript-3 Positive Exosomes to Regulate Natural Killer Function , 2008, PloS one.
[36] J. Burnett,et al. RNA-based therapeutics: current progress and future prospects. , 2012, Chemistry & biology.
[37] CD90+ liver cancer cells modulate endothelial cell phenotype through the release of exosomes containing H19 lncRNA , 2015, Molecular Cancer.
[38] J. Burthem,et al. Molecular pathogenesis of chronic myeloid leukaemia , 2003, Expert Reviews in Molecular Medicine.
[39] B. Druker,et al. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. , 2000, The Journal of clinical investigation.
[40] S. Raimondo,et al. Citrus limon-derived nanovesicles inhibit cancer cell proliferation and suppress CML xenograft growth by inducing TRAIL-mediated cell death , 2015 .
[41] Junfeng Zhang,et al. Identification and Characterization of 293T Cell-Derived Exosomes by Profiling the Protein, mRNA and MicroRNA Components , 2016, PloS one.
[42] E. Horváth-Puhó,et al. Chronic myeloproliferative neoplasms and risk of osteoporotic fractures; a nationwide population‐based cohort study , 2013, British journal of haematology.